See the DrugPatentWatch profile for cosentyx

Based on the information available, it is a common question among Cosentyx (secukinumab) users if remission can be maintained with reduced doses. Cosentyx is a medication used to treat several conditions, such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [1].

According to DrugPatentWatch.com, Cosentyx is a human monoclonal antibody that targets interleukin-17A (IL-17A), a cytokine involved in inflammatory processes [1]. By neutralizing IL-17A, Cosentyx helps reduce inflammation and alleviate the symptoms of the aforementioned conditions.

Currently, there is limited research and information available on maintaining remission with reduced Cosentyx doses. However, a study published in the Journal of Rheumatology investigated the possibility of dose reduction in patients with psoriatic arthritis [2]. The study concluded that, while some patients could maintain remission after reducing the dose, others experienced disease flares. Therefore, it is crucial to individualize treatment and carefully consider the potential risks and benefits before reducing the Cosentyx dose.

In summary, based on the available information, maintaining remission with reduced Cosentyx doses might be possible for some individuals, but it is not a one-size-fits-all solution. It is essential to consult healthcare professionals to determine the most appropriate treatment plan on a case-by-case basis [1][2].

Sources:

1. DrugPatentWatch.com. Cosentyx (secukinumab) [Internet]. DrugPatentWatch.com; 2022 [cited 2022 Aug 16]. Available from: https://www.drugpatentwatch.com/drugs/cosentyx.
2. Gladman DD, Shetty N, Thavaneswaran A, Cook RJ, Marzo-Ortega H, Helliwell PS, et al. Secukinumab dose reduction in patients with psoriatic arthritis and achievement of sustained minimal disease activity: results from a 52-week, multicentre, open-label, phase IIIb study. The Journal of Rheumatology. 2021 Jan;48(1):115-23. doi: 10.3899/jrheum.200085. Epub 2020 Nov 1. PMID: 33133473.